Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial - Van den Bent, Martin J.; Smits, Marion; Reijneveld, Jaap; French, Pim; Clement, Paul; Vos, Filip; Wick, Antje; Mulholland, Paul; Taphoorn, Martin; Lewis, Joanne; Weller, Michael; Chinot, Olivier; et al. (The lancet. Oncology, 2018)
Gesehen am 10.03.2020